<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>DNA polymerase eta (pol η) is the only DNA polymerase causally linked to <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> in humans </plain></SENT>
<SENT sid="1" pm="."><plain>Inherited deficiency of pol η in the variant form of <z:e sem="disease" ids="C0043346" disease_type="Neoplastic Process" abbrv="">xeroderma pigmentosum</z:e> (XPV) predisposes to UV-light-induced <z:e sem="disease" ids="C0007114" disease_type="Neoplastic Process" abbrv="">skin cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Pol η-deficient cells demonstrate increased sensitivity to <z:chebi fb="2" ids="27899">cisplatin</z:chebi> and <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> chemotherapy </plain></SENT>
<SENT sid="3" pm="."><plain>We have found that XP30R0 fibroblasts derived from a patient with XPV are more resistant to cell kill by ionising radiation (IR) than the same cells complemented with <z:mp ids='MP_0002169'>wild-type</z:mp> pol η </plain></SENT>
<SENT sid="4" pm="."><plain>This phenomenon has been confirmed in Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells, which either expressed <z:mp ids='MP_0002169'>wild-type</z:mp> pol η or harboured a pol η deletion </plain></SENT>
<SENT sid="5" pm="."><plain>Pol η deficiency was associated with accumulation of cells in S-phase, which persisted after IR </plain></SENT>
<SENT sid="6" pm="."><plain>Cells deficient in pol η demonstrated increased homologous recombination (HR)-directed repair of double strand breaks created by IR </plain></SENT>
<SENT sid="7" pm="."><plain><z:mpath ids='MPATH_63'>Depletion</z:mpath> of the HR protein, X-ray repair cross-complementing protein 3 (XRCC3), abrogated the radioresistance observed in pol η-deficient cells as compared with pol η-complemented cells </plain></SENT>
<SENT sid="8" pm="."><plain>These findings suggest that HR mediates S-phase-dependent radioresistance associated with pol η deficiency </plain></SENT>
<SENT sid="9" pm="."><plain>We propose that pol η protein levels in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> may potentially be used to identify patients who require treatment with chemo-radiotherapy rather than radiotherapy alone for adequate <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> control </plain></SENT>
</text></document>